MedTrace Logo

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

NCT01923181 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 632

Last updated 2021-01-15

Study results available
· View outcomes & findings →

Summary

This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

semaglutide

Once-daily oral administration as tablets.

DRUG

semaglutide

Once-weekly,injected s.c./subcutaneously (under the skin) using a pen

DRUG

oral placebo

Once-daily oral administration as tablets.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-02
Primary Completion
2014-12-11
Completion
2014-12-11

Countries

  • United States
  • Austria
  • Bulgaria
  • Canada
  • Denmark
  • Germany
  • Israel
  • Italy
  • Malaysia
  • Serbia
  • South Africa
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01923181 on ClinicalTrials.gov